Dr. Missak Haigentz, MD
Claim this profileRutgers Cancer Institute of New Jersey
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
14 reported clinical trials
23 drugs studied
Area of expertise
1Lung Cancer
Stage IV
Stage I
Stage II
2Non-Small Cell Lung Cancer
Stage II
Stage III
Stage I
Affiliated Hospitals
Clinical Trials Missak Haigentz, MD is currently running
Chemotherapy + Immunotherapy
for Lung Cancer
The purpose of the research is to evaluate a new schedule of alternating cycles of induction chemoimmunotherapy (chemotherapy plus pembrolizumab) and immunotherapy (pembrolizumab) alone for the initial treatment of patients with advanced lung or head and neck cancers.
Recruiting1 award Phase 2
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
More about Missak Haigentz, MD
Clinical Trial Related4 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Missak Haigentz, MD has experience with
- Pembrolizumab
- Cisplatin
- Intensity-Modulated Radiation Therapy
- Paclitaxel
- Carboplatin
- 5Fluorouracil
Breakdown of trials Missak Haigentz, MD has run
Lung Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Oropharyngeal Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Missak Haigentz, MD specialize in?
Missak Haigentz, MD focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage I.
Is Missak Haigentz, MD currently recruiting for clinical trials?
Yes, Missak Haigentz, MD is currently recruiting for 6 clinical trials in New Brunswick New Jersey. If you're interested in participating, you should apply.
Are there any treatments that Missak Haigentz, MD has studied deeply?
Yes, Missak Haigentz, MD has studied treatments such as Pembrolizumab, Cisplatin, Intensity-Modulated Radiation Therapy.
What is the best way to schedule an appointment with Missak Haigentz, MD?
Apply for one of the trials that Missak Haigentz, MD is conducting.
What is the office address of Missak Haigentz, MD?
The office of Missak Haigentz, MD is located at: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey 08903 United States. This is the address for their practice at the Rutgers Cancer Institute of New Jersey.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.